AMP 2024 | 2024
Sarah B Kingan1, Guilherme De Sena Brandine1, Jocelyne Bruand1, Jeff Zhou1, Valeriya Gaysinskaya1, Janet Aiyedun1, Julian Rocha1, Duncan Kilburn1, Egor Dolzhenko1, Zoi Kontogeorgiou2, Anita Szabo3, Christina Zarouchlioti3, Robert Thaenert4, Pilar Alvarez Jerez5, Kimberley Billingsley5, Sonia Lameiras6, Sylvain Baulande6, Alice Davidson3, Georgios Koutsis7, Georgia Karadima2, Stéphanie Tomé8, Michael A Eberle1 1. Pacific Biosciences (PacBio), Menlo Park, United States, 2. National and Kapodistrian University of Athens, 1st Department of Neurology, Athens, Greece, 3. University College London, Institute of Ophthalmology, United Kingdom, 4. Quest Diagnostics, Marlborough, United States, 5. National Institutes of Health, Center for Alzheimer's and Related Dementias, National Institute on Aging, Bethesda, United States, 6. Institut Curie, PSL Research University, ICGex Next-Generation Sequencing Platform, Paris, France, 7. National and Kapodistrian University of Athens, Neurogenetics Unit, 1st Department of Neurology, Eginition Hospital, School of Medicine, Athens, Greece 8. Sorbonne Université, Inserm, Institut de Myologie, Centre de Recherche en myologie, Paris, France
Short tandem repeats (STRs) are DNA sequences composed of repetitions of 1 – 6 bp motifs. Expansions of STRs are the cause of over 60 monogenic diseases, including Huntington’s disease, fragile X syndrome, and amyotrophic lateral sclerosis1. In addition to their length, the pathogenicity of these STRs can be impacted by sequence composition, methylation status and mosaicism. One such example is the FMR1 repeat whose CGG repeat expansions are typically hypermethylated and where AGG interruption sequences can stabilize the repeat. Detecting all the characteristics associated with pathogenic repeat expansions traditionally required multiple assays, however long-read sequencing of unamplified DNA holds the promise to resolve all these features in a single assay.